Loading...
•
Dec 31, 2022
Milestone Pharmaceuticals Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year 2022 and provided a clinical and corporate update.
Key Takeaways
Milestone Pharmaceuticals reported their Q4 and full year 2022 financial results. They are on track for a New Drug Application (NDA) submission in the third quarter of this year.
Advanced etripamil for paroxysmal supraventricular tachycardia (PSVT) through the approval process and into launch
Remain on track for a New Drug Application (NDA) submission in the third quarter of this year
Welcomed Seth Fischer to the Board of Directors
Phase 3 trials completed
Milestone Pharmaceuticals
Milestone Pharmaceuticals
Forward Guidance
Milestone Pharmaceuticals expects year-end cash resources, together with $125 million proceeds from March 2023 strategic financing, to fund operations into mid-2025. NDA submission for etripamil in patients with PSVT expected for 3Q23.